Corbus Pharmaceuticals Holdings Inc functions in the healthcare sector of the United States. It is in the business of developing and commercializing drugs to cure chronic inflammatory diseases, cystic fibrosis, systemic sclerosis and skin-predominant dermatomyositis. Its main product candidate is Resuban, which is a synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression.